To determine whether the SPT-R signature can be used as an early indicator of SPT therapy response, we applied this signature to RNA-Seq data from the additional PDX tumors in our original study that measured tumor regression and tumor progression after SPT exposure (4). Here, AGXT is linked to neoplasm.